EB613

EB613 (and its related candidate EB612) is an orally delivered formulation of teriparatide, which is the 1-34 fragment of human parathyroid hormone (PTH). Developed by Entera Bio, the drug utilizes the proprietary N-Tab™ technology platform, which employs a synthetic absorption enhancer and a protease inhibitor to enable the oral delivery of large molecules and peptides that are typically degraded in the gastrointestinal tract. EB613 acts as an osteoanabolic (bone-building) agent by binding to the parathyroid hormone receptor, thereby stimulating osteoblast activity and increasing bone mineral density. It is primarily positioned as a once-daily oral treatment for post-menopausal women with osteoporosis and as a hormone replacement therapy for patients with hypoparathyroidism, offering a non-invasive alternative to traditional subcutaneous injections.

Other names

oral teriparatideoral PTH (1-34)oral hPTH(1-34)hPTH(1-34)PTH-1-34PTH1-34PTH 1-34teriparatide